August newsletter in 60 seconds
Our expert comment this month looks at personalised medicine, but more from a business point of view than a medical one. As LSIPR readers will know, personalised medicine is all about tailoring treatment to the individual, and that, of course, can be extremely complicated.
Simmons & Simmons hires new partner
Law firm Simmons & Simmons has expanded its Düsseldorf office with the addition of a new partner.
English High Court invalidates Symbicort patent
English High Court Justice Philip James Sales has found a patent covering AstraZeneca’s bestselling drug Symbicort invalid after a challenge by Israeli generic drug maker Teva.
WilmerHale adds Dentons litigator to London team
WilmerHale has added life sciences lawyer and IP litigation specialist Anthony Trenton to its practice in London.
Sandoz barred from making Remodulin generic until 2017
Novartis’s generic arm Sandoz may not market a generic version of Maryland-based United Therapeutics’ Remodulin hypertension drug, the US District Court for the District of New Jersey ruled on Friday (August 29).
FDA accepts generic applications for three-times-weekly Copaxone
The FDA has accepted applications by generic drug makers Mylan and Novartis subsidiary Sandoz for a three-times-weekly version of blockbuster drug Copaxone, it was announced yesterday.
Novartis sues Zydus over Alzheimer and Parkinson’s disease drug
Novartis Pharmaceuticals has launched a lawsuit against generics company Zydus Noveltech and its subsidiaries, accusing them of infringing patents relating to a drug used to treat Alzheimer’s and Parkinson’s disease.
Federal Circuit upholds invalidity decision on Humira patent
The US Court of Appeals for the Federal Circuit yesterday (August 21) upheld a lower court’s decision that a patent covering rheumatoid arthritis drug Humira (adalimumab) is invalid.
New Jersey court blocks Actavis’s generic Gralise
The US District Court for the District of New Jersey has ruled that Actavis may not launch a generic version of California-based Depomed’s Gralise (gabapentin), it has been announced.
GeneDx claims 11 Myriad patents are invalid
The molecular diagnostic testing company GeneDx has petitioned the US Patent and Trademark Office to invalidate 11 patents asserted by Myriad in a lawsuit filed against GeneDx in October 2013.
